Introduction
1 vagina. The use of mucoadhesive nanopharmaceuticals could ensure prolonged and intimate 1 contact with the mucus, which is a prerequisite for subsequent events leading to the enhanced 2 delivery of drugs to the underlying tissue, sustained and controlled drug release or the protection 18 We have attempted to classify the studied/proposed delivery systems according to date that the 19 delivery system was first proposed or developed, how close each system is to achieving 20 therapeutic success or clinical evaluation. These systems are not characterised in details, rather, 21 we have focused on their applicability to vaginal therapy. We have highlighted, where applicable, 22 the potential uses of particular system for the treatment of specific vaginal diseases to allow the 23 reader to access to this information in a straightforward manner. 
Nanoscale drug delivery systems with potential in topical vaginal drug delivery

Liposomes 2
Liposomes are biocompatible colloidal nanoparticles that are characterised by their lipid 3 composition, particle size distribution, number of lamellae and inner/outer aqueous phases, all of 4 which dictate their stability and interaction characteristics. Liposomes have been studied for more 5 than 40 years in many different therapies, due to their ability to carry a wide variety of drugs, 6 their structural versatility, and their physiological compatibility (Torchilin, 2005) . 7 The potential uses of liposomes in topical vaginal therapy were recognised relatively late 8 compared to their applications in parenteral and skin delivery. In late 1990ties, two groups 9 explored the applicability of liposomes in vaginal drug delivery. Jain and coworkers (1997) 10 proposed the use of liposomes for the intravaginal delivery of progesterone, whereas Foldvari and (Table 1) . 15 16 19 The potential of liposomes in the topical treatment of vaginitis was originally reported by Pavelić 20 et al. (1999) . Three commonly applied drugs in the treatment of vaginal infections (clotrimazole, 21 metronidazole, and chloramphenicol) were entrapped in conventional lecithin liposomes and Two different approaches have been proposed to further improve the local delivery of liposomal 8 drugs to the infected vaginal site. One of these approaches is to enhance the ability of liposomes 9 to penetrate through the mucus using deformable (elastic) liposomes (Vanić et al., 2013) . Elastic 
4.1.1.. Fungal and bacterial infections
Viral infections
18
A considerable number of the nanopharmaceuticals developed for vaginal administration involve The system is also expected to exhibit an acidic pH similar to that of the normal vagina, should 2 not affect normal vaginal flora, and will be non-toxic to the protective genital mucosa. The 3 system should also be compatible with latex male condoms (Omar and Bergeron, 2011) . In 4 addition, it should be considered that microbicide-containing delivery systems can be diluted by 
19
The potential use of liposomal interferon α into genital wart tissues to provide a localised Carbopol gels were also reported to be capable of preserving the original size distributions of Moreover, its activity was not affected by acidic pH or by the presence of human serum proteins. 
In situ dendrimer-based gels
10
In situ-forming hydrogels, such as thermosensitive hydrogels, which form gels at body by the physicochemical features of the nanoparticles, particularly the surface-exposed molecules, 8 as well as their charge and size. Therefore, the major goals in designing nanoparticles as a 9 delivery system are to control the particle size, surface properties and release of 10 pharmacologically active agents to achieve site-specific drug activity at the therapeutically 11 optimal rate and dose regimen (Li and Huang, 2008).
12
Different types of nanoparticles were investigated as vehicles to improve the vaginal delivery of 13 drugs. These nanoparticles may be broadly classified as polymeric (synthetic and natural), 14 inorganic, or solid lipid nanoparticles. A new class of mucus-penetrating nanoparticles was 15 recently introduced, and is described in a separate chapter. The concept of using multivalent gold nanoparticles to inhibit HIV fusion was first introduced 
Solid lipid nanoparticles
15
Solid lipid nanoparticles (SLNs) were proposed as an alternative to polymeric nanoparticles.
16
They are spherical particles in the nanometer range, built of solid lipids and emulsifiers. SLNs 
Other nanopharmaceuticals 7
Several nanopharmaceuticals are emerging in the literature as potential drug delivery systems.
8
Most of these agents, such as cyclodextrin complexes, micelles, or niosomes have been The cyclodextrins were also studied as nanocarriers for anti-HIV agents. UC781, a highly potent specify the virus target. These polymeric micelles are designed to target a specific virus type, 19 attach to the virus particle, and engulf or coat the virus particle, thereby neutralising the virus's 20 infectivity and further, destabilize and possibly dismantle the virus particle. This approach is 21 certainly promising with respect to the challenge of developing of an efficient nano-microbicide.
22
However, a comprehensive explanation for the observed efficacy has yet to emerge, and its 1 effectiveness is tentatively attributed to the complex mechanism of action of the nanomaterials 
11
The surface properties of particles play an important role in their retention and delivery capacities 12 once in contact with the mucus. The surface charge and chemistry determine the attraction or 13 repulsion of the mucin fibres, whereas the size of the particle controls its ability to fit within the 14 mucin mesh pores. Therefore, it is clear that the diffusion rate of the nanoparticles is a 15 consequence of bonding to mucin fibres and particle size. Stronger bonds between mucin and the 
20
These findings indicate that the issue of mucoadhesion or mucoresistance must be addressed. To
21
summarise the discrepancies and possible mechanisms of drug delivery into the vaginal 22 epithelial, we propose a set of characteristics of nanodelivery systems that must be clarified to 1 achieve optimal drug therapy ( Figure 2 ). 
Toxicity issues 3
Nanotoxiclogy is a relatively new discipline that focuses on the reaction between the highly 4 increased reactive surfaces of nanomaterials, nanoparticles, and so-called "wet biochemistry". Tables with Table legends 2 
